Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 662 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Valeant takes over Visudyne from QLT

Valeant made $62.5m upfront payment for US rights and available inventories for Visudyne and another $50m for rights to non-US royalties on Visudyne sales. QLT is also entitled